from transcript. Turning to Slide 13, our team will be supporting two abstracts at the upcoming American College of Cardiology meeting in Chicago later this month. The data being presented by investigators at ACC25 will further enhance the medical community’s understanding regarding the potential mechanistic activities of EPA administered clinically in the form of Vascepa icosapent ethyl in reducing cardiovascular events in at risk patients. Specifically, the data will focus on the antioxidant effects of EPA on lipoprotein Lp enriched plasma and the effects of a GLP one receptor agonist in combination with EPA on the expression of antioxidant proteins in the endothelial cells in vitro. High Lp concentrations are associated with increased CD event risk and people with high levels face a two to four times greater risk of having an early event. With about twenty percent of the global population affected, research is crucial for understanding and addressing elevated Lp and the medical community has increased its focus on Lp as a key cardiovascular risk factor.
Market Data 
Markets 
AI
